NYSE:BHCPharmaceuticals
Xifaxan Win And Bausch Plus Lomb Spinoff Plans Reframe Bausch Health
Bausch Health Companies (NYSE:BHC) reported a major legal win that secures patent protection for its gastrointestinal drug Xifaxan.
The outcome reduces the risk of near term generic competition for Xifaxan, a key product in the company’s portfolio.
Management also confirmed further progress on plans to partially spin off Bausch + Lomb through a separate public listing.
Bausch Health Companies, trading at $5.73, has seen pressure on its share price over multiple time frames, with a 20.5%...